Symbicort (budesonide/formoterol) will be used more for COPD

April 2009

Symbicort (budesonide/formoterol) will be used more for COPD.

It's now the second corticosteroid/beta-agonist combo approved for maintenance of COPD...along with Advair (fluticasone/salmeterol).

But these are NOT first-line therapies.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

proton pump inhibitors (PPIs) might DECREASE the efficacy of clopidogrel (Plavix)
Shortages alternatives to oxycodone
Cardiology whether it's HARMFUL to combine an ACE inhibitor and ARB
Respiratory & Allergy Symbicort (budesonide/formoterol) will be used more for COPD
Respiratory & Allergy patients on Afrin or other nasal decongestants get rebound congestion
Pediatrics Miralax is being used more to treat constipation in kids
Psychiatry how to treat dementia associated with Parkinson's
Psychiatry metabolic acidosis in patients taking the antiepileptic, zonisamide (Zonegran, etc)
Antithrombotics when and how to use vitamin K to reverse the effects of warfarin
Gastroenterology Metoclopramide will have a new MedGuide and black box warning about the risk for tardive dyskinesia
Diabetes controversy about using glyburide for type 2 diabetes
Practice How should you handle an Rx written for the prescriber's personal or family use
Gout Uloric (YOU-lor-ik, febuxostat) is the first new chronic treatment for gout in over 40 years